Table 2.
Prednisone dose (mg/d)
| Drug | Baseline | 2 months | 6 months | 12 months | Comparisons |
||
|---|---|---|---|---|---|---|---|
| A | B | C | |||||
| Heart and liver | |||||||
| Alendronate | 24.2 ± 1.2a | 10.9 ± 1.2 | 5.9 ± 1.2 | 3.6 ± 1.3 | 0.07 | 0.48 | 0.83 |
| Zoledronate | 17.8 ± 1.2a | 9.2 ± 1.3 | 5.1 ± 1.3 | 2.5 ± 1.3 | |||
| Reference | 21.5 ± 2.0 | 10.1 ± 1.4 | 5.5 ± 1.3 | 3.8 ± 1.0 | |||
| Heart | |||||||
| Alendronate | 29.0 ± 1.7a | 14.1 ± 1.7 | 7.6 ± 1.7 | 5.8 ± 1.9 | 0.16 | 0.43 | 0.93 |
| Zoledronate | 20.9 ± 1.6a,b | 11.5 ± 1.7 | 6.3 ± 1.7 | 3.6 ± 1.8 | |||
| Reference | 26.3 ± 2.6b | 12.8 ± 1.8 | 7.4 ± 1.7 | 5.5 ± 1.3 | |||
| Liver | |||||||
| Alendronate | 16.8 ± 1.0a | 6.0 ± 1.0 | 3.3 ± 1.0 | 0.3 ± 1.1 | 0.19 | 0.67 | 0.56 |
| Zoledronate | 13.6 ± 1.1a | 5.4 ± 1.1 | 3.3 ± 1.1 | 0.7 ± 1.1 | |||
| Reference | 14.0 ± 1.0 | 4.7 ± 0.7 | 1.9 ± 0.6 | 0.3 ± 0.3 | |||
Data are expressed as mean ± se. Boldface data are statistically different from baseline within group. A shared superscript indicates a significant difference between the groups at that time-point. Comparisons: A, Alendronate vs. zoledronate group by time interaction; B, zoledronate vs. reference group by time interaction; C, alendronate vs. reference group by time interaction.